BBIO BridgeBio Pharma

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT.

To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors section of the BridgeBio website at . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on , , and .

BridgeBio Media Contact:

Bubba Murarka, Executive Vice President

  

(650)-789-8220

BridgeBio Investor Contact:

Chinmay Shukla, VP Strategic Finance



EN
07/05/2025

Underlying

BBIOBridgeBio Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BridgeBio Pharma

 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healt...

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET. To access the live webcast of BridgeBio’s presentation during the fireside chat, please visit the “Events...

June 2, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients...

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients: - In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placebo-...

May 20, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

Early and Sustained Increase in Serum TTR Levels by Acoramidis Indepen...

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes - ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and...

May 19, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BBIO BridgeBio Pharm...

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever A...

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM - ACT-EARLY is a registrational, randomized, double blind, placebo controlled, event driven prevention study that will enroll ~600 asymptomatic carriers of a pathogenic TTR variant...

May 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch